In a majority of patients with advanced systemic mastocytosis (SM), neoplastic mast cells (MC) express the target receptor CD30.
Introduction
Systemic mastocytosis (SM) is a myeloid neoplasm defined by expansion and accumulation of neoplastic mast cells (MC) in various organs. [1] [2] [3] [4] [5] [6] Based on clinical presentation and SMrelated organ damage, indolent and aggressive variants of SM have been defined. [6] [7] [8] [9] [10] Patients with indolent SM (ISM) usually suffer from mediator-related symptoms and/or from the cosmetic consequences of the disease. Otherwise, however, ISM patients have a normal or almost near-normal life expectancy without overt hematologic problems. [1] [2] [3] [4] [11] [12] [13] [14] In contrast, patients with advanced SM, including aggressive SM (ASM) and MC leukemia (MCL), have a dismal prognosis with short survival-times. [11] [12] [13] [14] [15] [16] In these patients, the invasive growth of neoplastic MC in the bone marrow (BM), liver and other visceral organs leads to organ damage. [11] [12] [13] [14] [15] [16] Moreover, in advanced SM, neoplastic MC are often resistant against various cytoreductive drugs. [11] [12] [13] [14] [15] [16] [17] [18] Therefore, these patients are candidates for experimental therapies.
Indeed, several attempts have been made to develop more effective treatment approaches and to identify novel therapeutic targets in neoplastic MC. [17] [18] [19] [20] In a vast majority of all patients with advanced SM, the transforming KIT mutation D816V is displayed by neoplastic cells. [21] [22] [23] [24] This mutation causes ligand-independent activation of KIT and is considered to contribute to malignant expansion of MC in SM. [2] [3] [4] [5] [6] 25 Therefore, drugs interfering with the tyrosine kinase (TK) activity of KIT D816V have recently been employed. [17] [18] [19] [20] [26] [27] [28] [29] [30] [31] [32] These drugs include midostaurin (PKC412), nilotinib, and dasatinib. 19, [26] [27] [28] [29] [30] [31] [32] However, despite impressive effects in cell line models and a clinical trial employing PKC412, these drugs may not be sufficient to induce long-lasting complete responses in ASM and MCL. More recently, we have shown that combinations of various KIT TK inhibitors (TKI) exert synergistic growth-inhibitory effects on neoplastic MC. 19, 27, 32 However, in neoplastic MC bearing KIT D816V, only few drug combinations induced synergistic effects. 32 Therefore, current research is seeking new targets and targeted drugs for ASM and MCL.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From of Hodgkin´s disease and ALK+ anaplastic large cell lymphomas. 33, 34 Other hematologic neoplasms are usually CD30-negative. However, recent data suggest that neoplastic MC in advanced SM also express the Ki-1 antigen in their cytoplasm. 35, 36 Notably, whereas in ISM, most neoplastic MC are CD30-negative cells, CD30 is expressed abundantly in the cytoplasm of MC in patients with ASM and MCL. 35, 36 More recent data suggest that neoplastic MC also express CD30 on their cell surface. 37 In this study we examined the expression of CD30 in various human MC lines and primary neoplastic MC and asked whether CD30 may serve as a therapeutic target.
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Materials and Methods

Isolation and culture of primary cells
Bone marrow (BM) samples were obtained from 45 patients with SM (ISM, n=25; SM-AHNMD, n=6; ASM, n=7; MCL, n=7) and 6 controls (normal/reactive BM). BM mononuclear cells (MNC) were isolated using Ficoll (Supplemental Table S1 ). All donors gave written informed consent. The study was approved by the ethics committee of the Medical University of Vienna. Human MC lines used in this study were HMC-1.1, HMC-1.2 19, 38 , MCPV-1.1, and MCPV-1. 4 . 39 In addition, we employed a canine mastocytoma cell line, C2 40 . A detailed description of cell lines is provided in the Supplement.
Multi-color flow cytometry
Heparinized BM cells (10 6 leukocytes/tube) of 51 donors were incubated with a PE-labeled CD30 monoclonal antibody (mAb), APC-labeled CD38 mAb, PE-Cy7-labeled CD117 mAb, APC-Cy7-labeled CD45 mAb, and Pacific Blue-labeled CD34 mAb (Supplemental Table S2 
Quantitative PCR (qPCR)
Total RNA was isolated from MNC of 29 patients with SM (ISM, n=17; SM-AHNMD, n=3;
ASM, n=5; MCL, n=4) using RNeasy MinElute TM Cleanup Kit (Qiagen, Hilden, Germany).
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The qPCR technique is described in the Supplement.
Measurement of soluble (s) CD30 in patients´ sera
Serum levels of sCD30 were determined in 10 healthy controls and in 36 patients with mastocytosis, including 6 with cutaneous mastocytosis (CM), 25 with ISM, 3 with ASM and 2 with MCL. Serum sCD30 levels were quantified using a commercial ELISA (ebioscience, San Diego, CA) following the manufacturer's instructions. The detection limit of sCD30 in this assay was 6.4 ng/ml.
Evaluation of apoptosis and cell cycle progression in mast cell (MC) lines
For flow cytometric determination of apoptosis and viability, AnnexinV/propidium iodide (PI) staining and active caspase-3 staining were performed as described. 27, 32 In brief, MCPV-1 cells, HMC-1 cells, and C2 cells were kept in control medium or brentuximab-vedotin (2.5-10 µg/ml) at 37°C for 96 hours. For AnnexinV/PI staining, cells were incubated with AnnexinV-FITC in binding-buffer containing HEPES (10 mM, pH 7.4), NaCl (140 mM) and CaCl 2 (2.5 mM). Thereafter, PI (1 µg/ml) was added and cells analyzed by flow cytometry. For active
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For cell cycle studies, cells were incubated in control medium or in brentuximab-vedotin (2.5-10 µg/ml) for 96 hours. Then, cells were resuspended in 300 µL permeabilization buffer (0.1% Na-acetate and 0.1% Triton X-100). Thereafter, 3 µl RNAse (100 µg/ml) and 25 µl PI were added. Cell cycle distribution was analyzed on a FACSCalibur as reported. 
Evaluation of activation-linked cells surface antigens by flow cytometry
For examination of drug effects on expression of CD63 and CD203c on BA and MC, flow cytometry was performed. HMC-1.1, HMC-1.2, MCPV-1.1, and BA from healthy donors (n=3) were incubated in brentuximab-vedotin (0.1-10 µg/ml) or control medium for 30 minutes (37°C). Cell lines were then examined for expression of CD63 and CD203c using mAb (Supplemental Table S2 ) by flow cytometry. Drug exposed primary BA were further incubated with anti-IgE mAb E-124.2.8 (1 µg/ml) at 37°C for 15 minutes, washed, subjected to erythrocyte lysis, and analyzed by flow cytometry using mAb against CD63 and CD203c. 
Statistical Evaluation of Data
Significances in differences in growth and apoptosis were determined by the Student's t test for dependent samples. Results were considered significant when p<0.05. Drug interactions (additive, synergistic, and antagonistic) were examined by calculating combination index (CI) values using CalcuSyn software (Biosoft, Cambridge, UK). 42 A CI value of 1 indicates an additive effect, whereas CI values below 1 indicate synergistic drug effects.
Results
Neoplastic MC express cell surface CD30
As assessed by flow cytometry, CD30 was expressed on neoplastic MC in 3/25 patients (12%) with ISM, 4/7 (57%) with ASM and 4/7 (57%) with MCL ( Figure 1A) . In most patients, CD30 expression in MC was confirmed by immunohistochemistry on BM sections (Table 1) .
Confirming previous studies 35 , MC were found to express cytoplasmic CD30 in most patients with advanced SM examined. However, in some of these patients, neoplastic MC also stained negative for cytoplasmic CD30 (Table 1) . In most patients with ISM, neoplastic MC expressed only low amounts or no cytoplasmic CD30. We also found a correlation between the type of SM and surface CD30 expression on MC (Table 1 ). In particular, CD30 levels on MC in patients with ASM and MCL were higher than that in ISM (median CD30 MFI:
ASM/MCL, 4.24 versus ISM, 1.88, p<0.05) ( Table 1) (Table 1 and Supplemental Figure S1A ).
Detection of increased serum levels of sCD30 in advanced SM
The levels of sCD30 in the sera of healthy controls (n=10) ranged between 6.4 and 28.5 ng/ml (median 8.1 ng/ml). In patients with mastocytosis, increased levels of sCD30 were detected.
However, serum levels of sCD30 were found to vary among patients, and to correlate with the variant of disease ( Figure 2 ). In patients with CM (n=6) sCD30 levels were only slightly elevated (median: 11.2 ng/ml; range: 7.3-31.0 ng/ml). Higher levels of sCD30 were detected in 25 patients with ISM (median: 21.0 ng/ml; range: 7.1-149.0 ng/ml) ( Figure 2 ). The highest levels of sCD30 were measured in patients with ASM or MCL (n=5), with a median of 129.0 ng/ml (Figure 2 ). However, no significant correlation between serum tryptase and sCD30
concentrations was found in our SM patients (not shown).
Expression of CD30 in neoplastic MC is regulated by a MEK-dependent pathway
We next examined the regulation of expression of CD30 in neoplastic MC. In a first step, we Figure 3D ).
Brentuximab-vedotin induces apoptosis in CD30 + neoplastic MC
To investigate the mechanism of action of brentuximab-vedotin, we examined drug-exposed cells for signs of apoptosis by staining for AnnexinV/PI and active caspase-3. In these experiments, brentuximab-vedotin produced dose-dependent apoptosis in MCPV-1.1 cells and C2 cells, and, less effectively, in HMC-1.1 cells ( Figure 4A ). By contrast, no significant increase in the number of apoptotic cells was seen in drug-exposed HMC-1.2 and MCPV-1.4 cells ( Figure 4A ). Next, we examined the effects of brentuximab-vedotin on primary CD30
− neoplastic MC. As shown in Figure 4B , brentuximab-vedotin induced dosedependent apoptosis in CD30 + neoplastic MC in all patients tested, whereas CD30 − MC did not respond to brentuximab-vedotin.
Brentuximab-vedotin cooperates with PKC412 in inducing growth-inhibition
As visible in Figure 5A , brentuximab-vedotin and PKC412 were found to synergize in producing growth inhibition in all cell lines tested, including HMC-1.1, HMC-1.2, MCPV- 
Discussion
In advanced SM, the malignant expansion and accumulation of neoplastic MC in various organ systems leads to organ damage. [1] [2] [3] [4] [5] [6] [12] [13] [14] [15] [16] For these patients, no effective therapy is available and the prognosis is poor. However, during the past few years, a number of potentially useful drug targets have been identified in neoplastic MC. 6, 18, 31, [35] [36] [37] 39 One of these potential targets appears to be the Ki-1 antigen, CD30. In the current study, we provide evidence that CD30 is expressed on the surface of MC in advanced SM and that the CD30-targeting antibody-conjugate brentuximab-vedotin produces growth inhibition and apoptosis in neoplastic MC. Moreover, our data show that brentuximab-vedotin and PKC412 exert synergistic growth-inhibitory effects on neoplastic MC.
Recent data have shown that CD30 is expressed in the cytoplasm and on the surface of neoplastic MC in SM. [35] [36] [37] 43, [44] [45] [46] [47] In an initial report, Sotlar et al. described that CD30 is commonly and strongly expressed in the cytoplasm of neoplastic MC in advanced SM, whereas in most patients with ISM, neoplastic MC expressed only low amounts or do not exhibit cytoplasmic CD30. 35 In the current study, we were able to confirm that CD30 is expressed in the cytoplasm of neoplastic MC in advanced SM in most patients. In addition, our data show that in most patients with advanced SM, neoplastic MC express cell surface CD30, which is important in the context of new treatment concepts employing CD30-targeted therapy. Moreover, we found a rough correlation between surface expression of CD30 and more advanced stage of the disease and also between expression of cytoplasmic CD30 and surface CD30 expression. However, these correlations were not significant, and in some patients with ASM or MCL, MC did not exhibit CD30 on their cell surface. Moreover, we In a next step, we explored whether sCD30 is detectable in the serum of our patients with advanced SM. Indeed, we found increased levels of sCD30 in patients with SM compared to healthy controls. Increased sCD30 levels were found in all categories of SM, but not in patients with cutaneous mastocytosis. Moreover, the median sCD30 level was higher in patients with advanced SM compared to ISM. Collectively, these data suggest that neoplastic MC actively secrete CD30, especially in advanced SM. However, we were unable to show a correlation between sCD30 levels and serum tryptase levels in our patients.
The CD30-targeting antibody-drug-conjugate brentuximab-vedotin reportedly inhibits the growth of CD30 + lymphoma cells. [50] [51] [52] In the current study, we were able to show that Based on these data it seems tempting to propose a clinical trial exploring anti-neoplastic effects of the drug combination PKC412+brentuximab-vedotin in advanced SM. Patients with SM often suffer from mediator-related symptoms. In these patients, MC are not only increased in number but are also activated. In many cases, mediator release is triggered by IgE-dependent mechanisms, and the resulting symptoms represent a major clinical challenge. [1] [2] [3] [4] [5] [6] We were therefore interested to learn whether brentuximab-vedotin modulates histamine secretion from BA or MC. In initial safety-validation experiments, we were able to
show that brentuximab-vedotin does not induce or promote histamine release from BA or MC which is relevant clinically as it predicts that the drug will not induce anaphylactic reactions 
